Citations

Clear

148 citation(s) found for "Stock, W".

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML
Huang, Ying , Lance, Jennie Rachel, Mao, Hsiaoyin, Dunbar, Andrew , McNulty, Samantha N. , Baer, Maria R. , Kovacsovics, Tibor , Blum, William , Schiller, Gary J. , Olin, Rebecca L. , Foran, James M. , Litzow, Mark R. , Patel, Prapti A. , Boyiadzis, Michael , Collins, Robert H. , Chervin, Jordan , Vergilio, Jo‐Anne, Heerema, Nyla A. , Rosenberg, Leonard, Chen, Timothy L. , Yocum, Ashley O. , Druggan, Franchesca , Marcus, Sonja, Stefanos, Mona , Borate, Uma , Burd, Amy , Byrd, John C. , Stein, Eytan M. , Huang, Ying , Cai, Sheng F , Litzow, Mark R. , Lin, Tara L , Druker, Brian J , Mims, Alice S , Byrd, John C , Druley, Todd E. , Li, Yan , Stock, Wendy , Lin, Tara L. , Foster, Matthew C , Shoben, Abigail B. , Levine, Ross L.

Mayo Clinic

Blood Advances | October 23, 2023 | Volume: 8 | Issue: 2 | Pages: 429-440

10.1182/bloodadvances.2023010563 | PMID 37871309 Get It

Abstract Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy, we applied a risk-adapted approach to assess the efficacy of ENA monotherapy for patients aged ≥60 years with newly diagnosed IDH2-mutant AML in whom genomic profiling demonstrated that mutant IDH2 was in the dominant leukemic clone. Patients for whom ENA monotherapy did not induce a complete remission (CR) or CR with incomplete blood count recovery (CRi) enrolled in a phase 1b cohort with the addition of azacitidine. The phase 2 portion assessing the overall response to ENA alone demonstrated efficacy, with a composite complete response (cCR) rate (CR/CRi) of 46% in 60 evaluable patients. Seventeen patients subsequently transitioned to phase 1b combination therapy, with a cCR rate of 41% and 1 dose-limiting toxicity. Correlative studies highlight mechanisms of clonal elimination with differentiation therapy as well as therapeutic resistance. This study demonstrates both efficacy of ENA monotherapy in the upfront setting and feasibility and applicability of a risk-adapted approach to the upfront treatment of IDH2-mutant AML. This trial is registered at www.clinicaltrials.gov as #NCT03013998.
Statement from the Asia Summit: Current state of arrhythmia care in Asia
Agbayani, Michael‐Joseph F., Choi, Jong‐Il , Dan, Van Buu , Hanafy, Dicky A, Hurwitz, Jodie L. , Kalman, Jonathan M. , Khan, Aamir Hameed H., Khmao, Pichmanil , Ngarmukos, Tachapong , Nguyen, Son Thai Binh, Nwe, Nwe, Soejima, Kyoko , Stiles, Martin K. , TSAO, HSUAN‐MING , Tseveendee, Saruul, Shimizu, Wataru , Kusumoto, Fred , Apiyasawat, Sirin , Chen, Ming-Long , Ching, Chi Keong , Hanafy, Dicky Armein , Johar, Sofian , Krahn, Andrew D. , Nwe, Nwe, Oh, Seil

Mayo Clinic

Journal of Arrhythmia | September 27, 2023 | Volume: 40 | Issue: 1 | Pages: 1-16

10.1002/joa3.12935 Get It

AbstractOn May 27, 2022, the Asia Pacific Heart Rhythm Society and the Heart Rhythm Society convened a meeting of leaders from different professional societies of healthcare providers committed to arrhythmia care from the Asia Pacific region. The overriding goals of the meeting were to discuss clinical and health policy issues that face each country for providing care for patients with electrophysiologic issues, share experiences and best practices, and discuss potential future solutions. Participants were asked to address a series of questions in preparation for the meeting. The format of the meeting was a series of individual country reports presented by the leaders from each of the professional societies followed by open discussion. The recorded presentations from the Asia Summit can be accessed at https://www.heartrhythm365.org/URL/asiasummit‐22. Three major themes arose from the discussion. First, the major clinical problems faced by different countries vary. Although atrial fibrillation is common throughout the region, the most important issues also include more general issues such as hypertension, rheumatic heart disease, tobacco abuse, and management of potentially life‐threatening problems such as sudden cardiac arrest or profound bradycardia. Second, there is significant variability in the access to advanced arrhythmia care throughout the region because of differences in workforce availability, resources, drug availability, and national health policies. Third, collaboration in the area already occurs between individual countries, but no systematic regional method for working together is present.
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Bashey, Asad, Foran, James M. , Mawad, Raya, Short, Nicholas J. , Yılmaz, Musa , Kantarjian, Hagop M. , Odenike, Olatoyosi , Patel, Anand , Garcha, Raman, Ainsworth, William B., Clynes, Raphael , Kanodia, Jitendra , Ding, Ying , Li, Huajiang, Kye, Steve, Short, Nicholas , Patel, Anand , Mims, Alice S , Yilmaz, Musa , Kantarjian, Hagop , Ravandi, Farhad , Stock, Wendy

Mayo Clinic

Blood Advances | August 30, 2023 | Volume: 7 | Issue: 21 | Pages: 6492-6505

10.1182/bloodadvances.2023010956 | PMID 37647601 Get It

Abstract Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study’s primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312.
P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
Stein, Eytan M. , Shukla, Neerav , Khera, Nandita , Rosen, Galit, Ghiraldi, Rachel, Nguyen, Huy Van, McNeer, Nicole, Zwaan, C. Michel , Rubnitz, Jeffrey E. , Issa, Ghayas , Stock, Wendy , Žučenka, Andrius , Khazal, Sajad Jawad , Stieglitz, Elliot , Rubinstein, Jeremy , Nguyen, Huy Van

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e221187f

10.1097/01.hs9.0000969148.22118.7f Get It

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Byrd, Ken, Doucette, Kimberly, Mangan, James K. , Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Byrd, Ken, Masters, Gregory A. , Mims, Alice S , Uy, Geoffrey L. , Erba, Harry Paul

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e08838b7

10.1097/01.hs9.0000967380.08838.b7 Get It

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
Lennep, Jeanine E. Roeters van , Tokgözoğlu, Lâle , Badimón, Lina , Dumanski, Sandra M. , Gulati, Martha , Hess, Connie N. , Holven, Kirsten B. , Kavousi, Maryam , Kayıkçıoğlu, Meral , Lutgens, Esther , Stock, Jane K., Tybjærg‐Hansen, Anne, Benn, Marianne , Roeters van Lennep, Jeanine E , Michos, Erin D , Prescott, Eva , Wermer, Marieke J H , Benn, Marianne , Lutgens, Esther , Kavousi, Maryam , Michos, Erin D.

Mayo Clinic

European Heart Journal | July 26, 2023 | Volume: 44 | Issue: 39 | Pages: 4157-4173

10.1093/eurheartj/ehad472 | PMID 37611089 Get It

Abstract Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
Borate, Uma , Yang, Fei , Press, Richard D. , Ruppert, Amy S. , Caruthers, Sean, Zhao, Weiqiang , Vergilio, Jo‐Anne, Pavlick, Dean C. , Juckett, Luke, Norris, Brianna, Burd, Amy , Stein, Eytan M. , Patel, Prapti A. , Baer, Maria R. , Schiller, Gary J. , Blum, William , Kovacsovics, Tibor , Litzow, Mark R. , Foran, James M. , Heerema, Nyla A. , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Byrd, John C. , Byrd, John C. , Press, Richard , Bucy, Taylor , Litzow, Mark R. , Druker, Brian J , Mims, Alice S , Byrd, John C , Jones, Dan M. , Stock, Wendy , Levine, Ross L.

Mayo Clinic

Blood Advances | July 17, 2023 | Volume: 7 | Issue: 20 | Pages: 6048-6054

10.1182/bloodadvances.2022009008 | PMID 37459200 Get It

AbstractNext-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at different diagnostic laboratories has been studied in solid tumors but not in myeloid malignancies to date. To determine this interlaboratory concordance, we collected a total of 194 AML bone marrow or peripheral blood samples from newly diagnosed patients with AML enrolled in the Beat AML Master Trial (BAMT) at 2 academic institutions. We analyzed the diagnostic samples from patients with AML for the detection of pathogenic myeloid mutations in 8 genes (DNMT3A, FLT3, IDH1, IDH2, NPM1, TET2, TP53, and WT1) locally using the Hematologic Neoplasm Mutation Panel (50-gene myeloid indication filter) (site 1) or the GeneTrails Comprehensive Heme Panel (site 2) at the 2 institutions and compared them with the central results from the diagnostic laboratory for the BAMT, Foundation Medicine, Inc. The overall percent agreement was over 95% each in all 8 genes, with almost perfect agreement (κ > 0.906) in all but WT1, which had substantial agreement (κ = 0.848) when controlling for site. The minimal discrepancies were due to reporting variants of unknown significance (VUS) for the WT1 and TP53 genes. These results indicate that the various NGS methods used to analyze samples from patients with AML enrolled in the BAMT show high concordance, a reassuring finding given the wide use of NGS for therapeutic decision-making in AML.
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Byrd, Kenneth, Doucette, Kimberley , Mangan, James K. , Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Masters, Gregory A. , Mims, Alice S , Uy, Geoffrey L. , Erba, Harry Paul

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 7006-7006

10.1200/jco.2023.41.16_suppl.7006 Get It

7006 Background: Older adult patients (pts) with Philadelphia-chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) have poor survival with chemotherapy. The α-CD22 Ab-drug conjugate inotuzumab ozogamicin (InO) and α-CD19/CD3 T-cell engager blinatumomab (blina) were each superior to chemotherapy in Phase III studies in relapsed/refractory B-ALL. Because InO induces high CR rates and blina can induce durable remissions in low burden disease, we conducted a Phase II trial of induction InO then blina for older adults with newly-diagnosed (ND), Ph-, B-ALL. Methods: Eligible were pts ≥60 years old with ND, Ph-, CD22+ (≥20% of blasts) B-ALL without plan for allogeneic HCT (alloHCT). Pts with CNS leukemia or liver disease were excluded. Induction IA was InO 0.8 mg/m 2 day (d) 1, 0.5 mg/m 2 d8, d15 IV on a 21d cycle. Pts with adequate cytoreduction (marrow blasts by ≥50% or cellularity ≤20%) after IA went to IB if in CR/CRi (InO 0.5 mg/m 2 d1, d8, d15 IV; 28d cycle) or IC if no CR/CRi (InO 0.8 mg/m 2 on d1 and 0.5 mg/m 2 on d8 and d15 IV; 28d cycle). Those without cytoreduction to IA started course II blina. Pts without events in IA/B/C received course II blina CIV (9 mcg/d x 7d then 28 mcg/d x 21d; 14d break; 28 mcg/d x28d). Pts with CR/CRi to InO received 2 more 28d cycles of blina, others received 3 more. CNS prophylaxis was methotrexate 15 mg intrathecal x 8. The primary endpoint was 1-yr event-free survival (EFS) with a lower limit of a 90% CI for 1-yr EFS >10% defined as success. EFS was the time from therapy start to failure to achieve CR/CRh/CRi by end Course II, progression, relapse, or death, whichever occurred first. Results: Thirty-three eligible pts were treated (1 ineligible, 2 nd malignancy). The median age was 71 years (range 60-84). Median WBC count was 3,200/mcl (range 6-38,000). Median CD22 expression was 92% (range 21-100%). Eight pts had therapy-related ALL. The cumulative CR rates through Course IA/B/C and Course II were 85% and 97%, respectively (Table). With median follow up of 22 mo, the 1-yr EFS was 75% (95% CI 61-92%). The 2-sided 90% CI was 63-89% for 1-yr EFS with lower bound above 10% indicating regimen success. Twelve pts had events: 9 relapses, 2 deaths in remission (1 after alloHCT), and 1 death without remission from respiratory failure with sinusoidal occlusion syndrome of liver. The 1-yr OS was 84% (95% CI 72-98%). Nine pts have died, 6 after relapse. Conclusions: InO induction then blina consolidation is highly active for ND, Ph-, CD22+ B-ALL. The regimen is an option for older adults and a comparator regimen for future studies. Support: U10CA180821, U10CA180882, U10CA180820 https://acknowledgments.alliancefound.org . Clinical trial information: NCT03739814 . N=33 I A/B/C II Composite CR* 28 ( 85%) 32 ( 97%) CR 15 (45%) 19 (58%) CRh 11 (33%) 12 (36%) CRi 2 (6%) 1 (3%) Refractory 3 (9%) † - 1-yr EFS 75% (95% CI 61-92%) 1-yr OS 84% (95% CI 72-92%) *CR+CRh+CRi † 1 completed IA only
Atorvastatin Inhibits Low-Density Receptor-Related Protein 5-Mediated Ectopic Bone Formation in the Aortic Valves of Hyperlipidemic Rabbits
Rajamannan, Nalini M. , Subramaniam, M., Secreto, Frank J., McConnell, J. P., Sebo, Thomas J., Bonow, Robert O. , Spelsberg, Thomas C., Singh, Ravinder J. , Stock, Stuart R.

Mayo Clinic

Journal of Investigative Medicine | May 25, 2023 | Volume: 52 | Issue: 2_suppl_part_4 | Pages: 354-354

10.1177/108155890405202s49 Get It

Neoangiogenesis via Vegf Expression is Associated with An Osteoblast-Bone Formation in Calcified Rheumatic Heart Valves
Rajamannan, Nalini M. , Nealis, Thomas B., Thennepan, T., Carmichael, S., Rosengart, T., Fredrickson, J., Edwards, William D. , Bonow, Robert O. , Spelsberg, Thomas C., Stock, Stuart R.

Mayo Clinic

Journal of Investigative Medicine | May 25, 2023 | Volume: 52 | Issue: 2_suppl_part_2 | Pages: 383-383

10.1177/108155890405202s110 Get It